We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.
- Authors
Bekaii-Saab, Tanios; Phelps, Mitch A; Li, Xiaobai; Saji, Motoyasu; Goff, Laura; Kauh, John Sae Wook; O'Neil, Bert H; Balsom, Stephanie; Balint, Catherine; Liersemann, Ryan; Vasko, Vasily V; Bloomston, Mark; Marsh, William; Doyle, L Austin; Ellison, Gilian; Grever, Michael; Ringel, Matthew D; Villalona-Calero, Miguel A
- Abstract
Biliary cancers (BCs) carry a poor prognosis, but targeting the RAS/RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) pathway is of significance. Selumetinib is an inhibitor of MEK1/2, so this trial was designed to determine the safety and efficacy of selumetinib in BC.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Vol 29, Issue 17, p2357
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2010.33.9473